Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "DCGI"

147 News Found

We need to focus on quality and affordable manufacturing: Mandaviya
Policy | May 29, 2023

We need to focus on quality and affordable manufacturing: Mandaviya

Dr. Mandaviya urged the stakeholders to capitalize on the current opportunities


Health Minister Mandaviya inaugurates 8th International Conference on Pharma and Medical Device Sector
Policy | May 27, 2023

Health Minister Mandaviya inaugurates 8th International Conference on Pharma and Medical Device Sector

Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector


Emcure Pharmaceuticals to launch the750 mg injectable variant of ferric carboxymaltose
News | May 17, 2023

Emcure Pharmaceuticals to launch the750 mg injectable variant of ferric carboxymaltose

Single dose of Ferric Carboxymaltose (FCM) up to 750 mg of iron can be infused in 15 minutes


Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma
News | January 06, 2023

Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma

The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”


Aurobindo's subsidiary Tergene Biotech receives SEC recommendation for pneumococcal 15 valent vaccine
Drug Approval | December 28, 2022

Aurobindo's subsidiary Tergene Biotech receives SEC recommendation for pneumococcal 15 valent vaccine

The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come


Hetero's COVID-19 oral drug gets WHO prequalification
News | December 27, 2022

Hetero's COVID-19 oral drug gets WHO prequalification

WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission


Biocon initiates clinical study of Itolizumab for ulcerative colitis in India
Clinical Trials | December 15, 2022

Biocon initiates clinical study of Itolizumab for ulcerative colitis in India

This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study


Presss note on WHO Medical product alert regarding Maiden Pharmaceuticals
News | October 07, 2022

Presss note on WHO Medical product alert regarding Maiden Pharmaceuticals

DSCO has requested WHO to share at the earliest with CDSCO the report on establishment of causal relation to death with the medical products in question etc.


Biological E. announces CDSCO recommendation of its infant’s vaccine
Drug Approval | September 01, 2022

Biological E. announces CDSCO recommendation of its infant’s vaccine

Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)


Glenmark Pharma and SaNOtize announce Peer Reviewed Publication of its Phase 3 Clinical Trials on SaNOtize's Novel Nitric Oxide Nasal Spray
Clinical Trials | July 14, 2022

Glenmark Pharma and SaNOtize announce Peer Reviewed Publication of its Phase 3 Clinical Trials on SaNOtize's Novel Nitric Oxide Nasal Spray

The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.